Document:

EX-10.1

 Exhibit 10.1 

GENETRON HOLDINGS LIMITED 
 RULES
OF THE 2019 GENETRON HEALTH 
 SHARE INCENTIVE PLAN 
  

			
	Committee’ Adoption:	  	July 2, 2019
		
	Expiry Date:	  	July 2, 2019

 Table of Contents 

 

					
	Contents	  	Page	 
		
	 1   Definitions
	  	 	1	 
		
	 2   Granting Awards
	  	 	3	 
		
	 3   Before Vesting
	  	 	5	 
		
	 4   Vesting
	  	 	6	 
		
	 5   Reduction or clawback of Awards
	  	 	9	 
		
	 6   Leaving employment and death
	  	 	10	 
		
	 7   Change of Control
	  	 	11	 
		
	 8   Changing the Plan and termination
	  	 	12	 
		
	 9   General
	  	 	12	 

  
 i 

	1	 Definitions 

In these rules: 

“Adoption Date” means July 2, 2019, being the date on which the Plan was adopted by the Company; 

“Award” means an RSU, Restricted Shares or an Option; 

“Award Agreement” means the agreement referred to in rule 2.4; 

“Award Date” means the date on which an Award is granted by deed under rule 2.2 (Terms of Awards); 

“Change of Control” means the occurrence of any one or more of the following events: 

 

	 	(a)	 approval by shareholders of the Company (or, if no shareholder approval is required, by the Board alone) of the
complete dissolution or liquidation of the Company; 

  

	 	(b)	 any person becomes the beneficial owner as defined under the Exchange Act Rule 13d-3, directly or indirectly,
of securities of the Company representing more than 50% of the combined voting power of the Company’s outstanding securities entitled to vote generally in the election of directors or appoints a majority of the Board; 

 

	 	(c)	 the consummation of (i) a merger or consolidation of the Company or any of its subsidiaries with any other
corporation or entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or being
converted into voting securities of the surviving entity or, if applicable, the ultimate parent thereof) at least 50% of the combined voting power of the securities of the Company or such surviving entity or parent outstanding immediately after such
merger or consolidation or (ii) any sale, lease, exchange or other transfer to any person of assets of the Company and/or any of its subsidiaries, in one transaction or a series of related transactions, having an aggregate fair market value of
more than 50% of the fair market value of the Company and its subsidiaries immediately prior to such transaction(s); or 

  

	 	(d)	 any analogous situation as determined by the Committee solely at its discretion; provided that, in the case of
each of (a) and (b), a Change of Control shall not be deemed to have occurred until the Committee has determined by resolution of the Committee that such event has occurred; provided further that change of control will not occur for purposes of
Awards that are subject to Section 409A of the Code unless the event also constitutes a change of control under 409A of the Code; 

“Code” means the Internal Revenue Code of 1986 of the United States, as amended; 

“Committee” means, subject to rule 7.6, the board of directors of the Company or the management committee of the Company to be
established by the board of directors unless otherwise resolved by the board of directors; 
 “Company” means Genetron
Holdings Limited; 

  
 1 

 “Control” means the possession, direct or indirect, of the power to direct,
or cause the direction of, the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise; 

“Dividend Equivalent” means an amount equal to the ordinary dividends payable on the number of Vested Shares between the Award
Date and Vesting (or, in the case of Options, the date of exercise); 
 “Employee” means a person who has Employment
Relationship with the Company or a Related Entity; 
 “Employment Relationship” means labor or employment relationship
between the employee and the Company or a Related Entity; 
 “Exchange Act” means the Securities Exchange Act of 1934, as
amended; 
 “Final Lapse Date” means the tenth anniversary of the Award Date of an Option or any earlier date set under rule
2.2 (Terms of Awards); 
 “Grant” means the offer of the grant of an Award made in accordance with this Plan; 

“Grantor” means, in respect of an Award, the Company or any other entity which grants that Award or has agreed to satisfy it;

 “Grantee” means any Participant who accepts a Grant in accordance with the terms of the Plan, or (where the context so
permits) any person who is entitled to any Award in consequence of the death of the original Grantee; 
 “Group” means the
Company and its Related Entities; 
 “Leaving employment” has the meaning given in rule 6.4; 

“Listing” means a firm commitment underwritten public offering of the Shares of the Company (or depositary receipts or
depositary shares thereof) on the Stock Exchange; 
 “Listing Rules” means the rules governing the Listing of securities on
the Stock Exchange as amended from time to time; 
 “Normal Vesting Date” means the date set by the Committee for Vesting of
an Award under rule 2.2 (Terms of Awards); 
 “Option” means a right to acquire Shares granted under the Plan on payment of
the Option Price or a Phantom Option; 
 “Option Price” means the amount (if any) payable on the exercise of an Option, as
specified under rule 2.2.7; 
 “Participant” means a person holding an Award or their personal representatives; 

“Performance Condition” means a condition set for Vesting of an Award under rule 2.3; 

“Phantom Option” means an Option which will always be satisfied with a cash payment as described in rule 4.7; 

“Phantom RSU” means an RSU which will always be satisfied with a cash payment as described in rule 4.7; 

“Plan” means these rules known as “The 2019 Genetron Health Share Incentive Plan”, as changed from time to time;

  
 2 

 “Related Entity” means any entity that, directly or indirectly, Controls
the Company or is Controlled by the Company through shareholding relationship or contractual arrangements, or is under common Control with the Company (directly or indirectly), or in which the Company has a significant equity interest, as determined
by the Committee 
 “Restricted Shares” means Shares held in the name of or for the benefit of a Participant until Vesting
on the basis set out in the Award Agreement; 
 “Restricted Share Price” means the amount payable before grant of any
Restricted Shares as determined under rule 2.2.7; 
 “RSU” means a restricted stock unit which is a conditional right,
granted under the Plan, to acquire Shares following Vesting or a Phantom RSU; 
 “Shares” means ordinary shares in the share
capital of the Company, or if there has been a sub-division, reduction, consolidation, reclassification or reconstruction of the share capital of the Company, the shares forming part of the ordinary equity share capital of the Company of such
nominal amount as shall result from any such sub-division, reduction, consolidation, reclassification or reconstruction; 
 “Stock
Exchange” means the Stock Exchange of Hong Kong Limited, the New York Stock Exchange or the Nasdaq Stock Market; 

“Transfer Restrictions” means any restriction on transfer in securities imposed by regulation, statute, order, directive or
any code adopted by the Company as varied from time to time; 
 “Vesting” means, subject to the rest of these rules: 

 

	 	(a)	 in relation to an Option, the Option becoming exercisable; 

 

	 	(b)	 in relation to an RSU, the Participant becoming entitled to have Shares issued or transferred to them; and

  

	 	(c)	 in relation to Restricted Shares, means the restrictions set out in the Award Agreement ceasing to have effect
as described in rule 4.5 (Consequences of Vesting for Restricted Shares). 

  

	2	 Granting Awards 

 

	2.1	 Eligibility 

The Committee may decide that an Award will be granted to: 
  

	 	2.1.1	 any Employee or director of the Group; or 

 

	 	2.1.2	 any consultant, adviser or other person who provides services to the Group, 

selected by the Committee. 

Unless the Committee considers that special circumstances exist, an Award may not be granted to a person who, on the Award Date, has given or
received notice of termination of employment or engagement, whether or not such termination is or would be lawful. 

  
 3 

	2.2	 Terms of Awards 

When granting an Award, the Committee will determine the following in relation to the Award: 

 

	 	2.2.1	 whether the Award is: 

 

	 	(i)	 an RSU; 

  

	 	(ii)	 an Option; 

  

	 	(iii)	 a Phantom Option; 

  

	 	(iv)	 a Phantom RSU; 

  

	 	(v)	 an award of Restricted Shares, 

or a combination of these; 
  

	 	2.2.2	 the number of Shares subject to the Award or the basis on which the number of Shares subject to the Award will
be calculated; 

  

	 	2.2.3	 the terms of any Performance Condition specified under rule 2.3; 

 

	 	2.2.4	 the Normal Vesting Date(s) and, if there is more than one, the number of Shares to which each Normal Vesting
Date relates or how that will be determined; 

  

	 	2.2.5	 whether the Participant is entitled to receive any Dividend Equivalent and, if so, the basis on which it will
be determined; 

  

	 	2.2.6	 the Award Date; 

  

	 	2.2.7	 in the case of Restricted Shares, the Restricted Share Price (which shall in no circumstances be less than the
par value of the Restricted Shares unless such Restricted Shares are already in issue and have already been fully paid for at or above par value); 

  

	 	2.2.8	 in the case of an Option: 

 

	 	(i)	 the Option Price (which shall in no circumstances be less than the par value of the Shares acquired on the
exercise of the Option unless such Shares are already in issue and have already been fully paid for at or above par value); and 

  

	 	(ii)	 the Final Lapse Date. 

 

	2.3	 Performance Conditions 

When granting an Award, the Committee may make its Vesting or exercise conditional on the satisfaction of one or more conditions which may be
linked to the performance of the Participant, the Group or business unit in which the Participant works or any other factor. 
 A Performance
Condition must be specified at the Award Date but the Committee may waive or change a Performance Condition in accordance with its terms or if anything happens which causes the Committee reasonably to consider it appropriate to do so. If no
Performance Conditions are specified at the Award Date, a negative statement to that effect must be provided. 
  

	2.4	 Award Agreements 

 

	 	2.4.1	 An Award will only be effective once the Participant has signed an Award Agreement. If the Participant does not
sign the Award Agreement by the deadline and in the manner specified by the Committee for the Award, the Award will be deemed to have never been granted. 

  
 4 

	 	2.4.2	 The terms of the Award Agreement will be determined by the Committee but will be consistent with these rules.

  

	 	2.4.3	 In the case of an award of Restricted Shares, the Award Agreement must provide that, to the extent that the
Award lapses under the Plan, the Shares shall be surrendered to or repurchased by the Company and the Participant will immediately transfer his interest in the Shares, for no consideration or nominal consideration, to any person (which may include
the Company, where permitted) specified by the Committee. 

  

	 	2.4.4	 By signing the Award Agreement, the Participant agrees to be bound by these rules (as amended from time to
time) and the terms set for the Award under rule 2.2 as if they had formed part of the Award Agreement. 

  

	2.5	 Procedure on grant of Restricted Shares 

 

	 	2.5.1	 The Participant must, in relation to an Award of Restricted Shares: 

 

	 	(i)	 sign the Award Agreement; and 

 

	 	(ii)	 sign any documentation, including a power of attorney or blank stock transfer form or any tax elections
requested by the Committee to give effect to the Award; and 

  

	 	(iii)	 pay the Restricted Share Price or make arrangements for its payment which are satisfactory to the Committee.

  

	 	2.5.2	 If the Participant does not do all these things in the manner and by the date(s) specified by the Committee,
the Award will lapse at the end of that period. 

  

	 	2.5.3	 On (or as soon as reasonably practicable after) the date on which the Participant has complied with all their
obligations under rule 2.5.1, the Grantor will procure that the relevant number of Shares are issued or transferred to the Participant or to another person to be held for the benefit of the Participant under the terms of the Plan on such basis as
the Committee may specify. 

  

	 	2.5.4	 The Grantor may retain the share certificates or other documents of title relating to any Restricted Shares.

  

	3	 Before Vesting 

 

	3.1	 Rights 

  

	 	3.1.1	 A Participant is not entitled to vote, to receive dividends or to have any other rights of a shareholder in
respect of Shares subject to an Option or RSU until the Shares are issued or transferred to the Participant. 

  

	 	3.1.2	 Except to the extent specified in the Award Agreement, a Participant will have all rights of a shareholder in
respect of Restricted Shares until the Award lapses. 

  

	3.2	 Transfer Restrictions 

No right of interest of a Participant in any Award may be pledged, encumbered, or hypothecated to or in favor of any party other than the
Group, or shall be subject to any lien, obligation, or liability of such Participant to any other party other than the Group. This rule 3.2 does not apply: 
  

	 	3.2.1	 to the transmission of an Award on the death of a Participant to the personal representatives; or

  
 5 

	 	3.2.2	 to the assignment of an Award, with the prior written consent of the Committee, subject to any terms and
conditions the Committee impose. 

  

	3.3	 Adjustment of Awards 

 

	 	3.3.1	 If there is: 

  

	 	(i)	 a variation in the equity share capital of the Company, including a capitalisation or rights issue,
sub-division, consolidation or reduction of share capital; 

  

	 	(ii)	 a demerger (in whatever form); 

 

	 	(iii)	 a special dividend or distribution; or 

 

	 	(iv)	 any other corporate event which might affect the current or future value of any Award; 

the Committee may adjust the description, number and/or class of Shares or securities subject to an RSU or Option and/or the Option Price 

 

	 	3.3.2	 Subject to the Award Agreement, the Participant will have the same rights as any other shareholders in respect
of Restricted Shares where there is a variation or other event of the sort described in rule 3.3.1. Any shares, securities or rights allotted to a Participant as a result of such an event will be: 

 

	 	(i)	 treated as if they were awarded to the Participant under the Plan in the same way and at the same time as the
Restricted Shares in respect of which the rights were conferred; and 

  

	 	(ii)	 subject to the rules of the Plan and the terms of the Award Agreement. 

 

	3.4	 Repayment of Restricted Share Price on lapse 

The Grantor will repay the Restricted Share Price to the Participant if an Award of Restricted Shares lapses. If it lapses in part, a pro-rata
portion of the Restricted Share Price will be repaid. 
  

	4	 Vesting 

  

	4.1	 Timing of Vesting 

Subject to rule 4.2 (Delayed Vesting), an Award will normally Vest on the latest of: 

 

	 	4.1.1	 the date on which the Committee determines the extent to which any Performance Condition has been met;

  

	 	4.1.2	 any Normal Vesting Date; and 

 

	 	4.1.3	 the first date on which Vesting is not prevented by a Transfer Restriction. 

However, the Committee may in its sole discretion, at any time, decide that the Award will Vest on any earlier date and/or waive any
Performance Condition. 

  
 6 

	4.2	 Delayed Vesting 

Vesting is delayed in respect of a Participant’s Award, or any part of it, if any of the following circumstances apply on the anticipated
date of Vesting: 
  

	 	4.2.1	 if the Participant is subject to any Disciplinary Action; 

 

	 	4.2.2	 if the Participant’s employment has terminated or is about to terminate in circumstances where it is not
clear whether the Award should lapse under rule 6; or 

  

	 	4.2.3	 the Committee consider that it is necessary or appropriate to defer Vesting. 

In these cases, Vesting will not occur unless and until the Committee determine that the Award should Vest. 

“Disciplinary Action” for the purpose of this rule 4.2 (Delayed Vesting), means any enquiry or investigation by the Group into
the conduct, capability or performance of a Participant that may potentially lead to disciplinary action being taken against that Participant, and/or any disciplinary procedure (whether in accordance with any relevant contractual obligation, policy
or otherwise) that has been commenced by any member of the Group against a Participant; 
  

	4.3	 Consequences of Vesting for RSUs 

As soon as reasonably practicable following Vesting of an RSU, the Grantor will arrange (subject to rules 4.7, 4.8, 6.3 and 9.5) for the number
of Shares in respect of which the Award has Vested to be issued or transferred to, or to the order of, the Participant. 
  

	4.4	 Consequences of Vesting for Options 

 

	 	4.4.1	 A Participant may only exercise an Option to the extent it has Vested. 

 

	 	4.4.2	 To validly exercise an Option, the Participant must give notice in writing, in any form prescribed by the
Committee, to the Grantor or any person nominated by the Grantor and pay any Option Price or make arrangements reasonably satisfactory to the Committee for its payment. 

 

	 	4.4.3	 As soon as reasonably practicable following the valid exercise of an Option, the Grantor will arrange (subject
to rules 4.7, 4.8, 6.3 and 9.5) for the number of Shares in respect of which the Option has been exercised to be issued or transferred to, or to the order of, the Participant. 

 

	 	4.4.4	 The Option will lapse, at the latest, on the close of business on the Final Lapse Date. 

 

	 	4.4.5	 If an Option becomes exercisable or lapses under more than one provision of the rules of the Plan, the
provision resulting in the shortest exercise period or the earliest lapse will prevail. 

  

	4.5	 Consequences of Vesting for Restricted Shares 

With effect from the date of Vesting, the restrictions referred to in rule 2.4.3 and contained in the Award Agreement will cease to have
effect. Rule 4.8 will apply to any tax and social security contributions payable on Vesting. 
 If the Restricted Shares are not held by the
Participant, the Grantor will arrange for them to be transferred to or to the order of the Participant. 

  
 7 

	4.6	 Dividend Equivalent 

An RSU may include the right to receive a Dividend Equivalent which may be paid in cash or Shares (as determined from time to time by the
Committee). Dividend Equivalents will be paid to the Participant as soon as practicable after Vesting or, in the case of Options, exercise. 
  

	4.7	 Cash alternative 

The Committee may in its sole discretion decide on exercise of an Option or Vesting of an RSU that no Shares will be issued or transferred but
that, instead, the Participant will be paid a cash amount equal to the market value of the Shares which would otherwise be issued or transferred on the date of exercise or Vesting (as the case may be), less the Option Price, in the case of an
Option. 
 A Phantom Option or a Phantom Award will always be satisfied in this way. 

 

	4.8	 Tax 

  

	 	4.8.1	 The Participant will be responsible for all tax, social security contributions or other levies arising out of
or in connection with an Award and indemnifies the Group against any liability they may have to pay or withhold such liabilities. 

  

	 	4.8.2	 Without limiting this, the Group, the Grantor, any employing company or trustee of any employee benefit trust
may withhold such amount and make such arrangements as it considers necessary to meet any such liability to taxation or social security contributions in respect of Awards. These arrangements may include: 

 

	 	(i)	 reducing the number of Shares or the amount of cash to which the Participant would otherwise be entitled under
the Plan; 

  

	 	(ii)	 selling Shares on behalf of the Participant and retaining the proceeds to meet the liability;

  

	 	(iii)	 to the extent lawful, deducting the amount of the liability from any payment of salary or bonus or any other
payment due to the Participant. 

  

	 	4.8.3	 The Participant will be responsible for obtaining his or her own tax advice agrees not to take (or omit to
take) any action in connection with any Award in reliance on any statement as to the tax treatment of any Award made (or purported to be made) by or on behalf of the Group. No member of the Group will be responsible for the tax treatment or any
change in the tax treatment of any Award. 

  

	 	4.8.4	 To the extent that the Committee determines that any Award may become subject to Section 409A of the Code,
the Award shall incorporate the terms and conditions required by Section 409A of the Code. In the event that following the Adoption Date the Committee determines that any Award may be subject to Section 409A of the Code and related
Department of Treasury guidance (including such Department of Treasury guidance as may be issued after the Adoption Date), the Committee may adopt such amendments to the Scheme or adopt other policies and procedures (including amendments, policies
and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to: 

  

	 	(i)	 exempt the Award from Section 409A of the Code and/or preserve the intended tax treatment of the benefits
provided with respect to the Award; or 

  
 8 

	 	(ii)	 comply with the requirements of Section 409A of the Code and related U.S. Department of Treasury guidance.

  

	5	 Reduction or clawback of Awards 

 

	5.1	 Reduction 

Notwithstanding anything else in these rules, if any of the events specified in rule 5.3 occurs the Committee may, at any time before an Award
has Vested or been exercised and in its sole discretion, decide that: 
  

	 	5.1.1	 the number of Shares subject to any Award will be reduced; 

 

	 	5.1.2	 the Award will lapse (at a time they determine); 

 

	 	5.1.3	 the delivery of the Shares will be delayed until any action or investigation is completed; and/or

  

	 	5.1.4	 additional conditions will be imposed on the Vesting or exercise of the Award. 

 

	5.2	 Clawback 

Notwithstanding anything else in these rules, if any of the events specified in rule 5.3 occurs the Committee may, at any time within the
period of one year after an Award has Vested or been exercised and in its sole discretion, decide that the Participant: 
  

	 	5.2.1	 must transfer to or to the order of the Company a number of Shares which is equal to (or less than) the number
of Shares issued or transferred to them pursuant to the Award; and/or 

  

	 	5.2.2	 pay to or to the order of the Company an amount representing the value of the Shares acquired under the Award;
and/or 

  

	 	5.2.3	 pay to or to the order of the Company an amount equal to any cash payment made to them pursuant to the Award.

  

	5.3	 Events giving rise to reduction or clawback 

 

	    	 The events are: 

  

	 	5.3.1	 The Participant has left employment and the Committee exercises its discretion under rule 6 to allow the Award
not to lapse in full but facts emerge which, if known, would have caused the Committee to exercise its discretion differently (or not exercise it). 

  

	 	5.3.2	 There is a financial irregularity such as misstatement of accounts. 

 

	 	5.3.3	 Any member of the Group is found guilty of any offence for which the Participant is wholly or partly
responsible or accountable. 

  

	 	5.3.4	 The Participant breaches on any restrictions on competing with or soliciting clients or Employees from the
Group, whether under the Participant’s engagement or any arrangements made in connection with leaving employment. 

  
 9 

	 	5.3.5	 Results announced for any financial year before Vesting have subsequently appeared materially financially
inaccurate or misleading as determined by the Committee. 

  

	 	5.3.6	 Any error or a material misstatement has resulted in an overpayment or over-allocation to the Participant,
whether in the form of Awards under the Plan or otherwise. 

  

	 	5.3.7	 The Participant’s behaviour has fallen below that which would have been expected and the Committee
determine that this has resulted in material reputational damage to the Group. 

  

	6	 Leaving employment and death 

 

	6.1	 General rule 

Subject to rule 6.2, an Award will lapse on the date the Participant leaves employment, whether or not it has vested. 

 

	6.2	 Exceptions 

  

	 	6.2.1	 Where rule 6.1 applies, the Committee may in its sole discretion decide that: 

 

	 	(i)	 the Award will lapse to a lesser extent than specified in rule 6.1 (and continue in effect as to the balance);
and/or 

  

	 	(ii)	 the Award will Vest or become exercisable on the date of leaving (or such later date as the Committee may
specify); and/or 

  

	 	(iii)	 Vesting or exercise of the Award will be subject to such additional conditions as the Committee may specify;
and/or 

  

	 	(iv)	 the Award will lapse on such date as the Committee may specify. 

 

	 	6.2.2	 An Award of Restricted Shares which has Vested will not lapse if the Participant leaves employment.

  

	6.3	 Death 

If a Participant dies, their Awards will Vest on the date of death to the extent determined by the Committee at the date of death and will
lapse as to the balance. 
 The Grantor will only arrange for Shares to be issued or transferred, or cash paid to the personal
representatives of a deceased Participant if they have produced such evidence as the Committee may require of their status as such. The receipt of any person who has produced such evidence will discharge the Grantor from any obligation to the
Participant or their estate. 
  

	6.4	 General 

  

	 	6.4.1	 A Participant will only be treated as “leaving employment” when they are no longer an Employee
or director of the Group or a consultant, adviser or other person who provides services to the Group. 

  

	 	6.4.2	 Unless the Committee decide otherwise, a Participant will be treated as leaving employment on the date on which
they give or receive notice terminating their office or employment or other arrangement under which they provide services, whether or not such termination is or would be lawful. 

  
 10 

	7	 Change of Control 

 

	7.1	 Application 

This rule applies if a Change of Control occurs and a Participant’s Awards are not converted, assumed, or replaced by a successor. 

 

	7.2	 Vesting or Awards 

 

	 	7.2.1	 Subject to rule 7.4, where this rule applies, the Award will Vest to the extent determined by the Committee,
having regard to any Performance Condition and amount of time to run to the Normal Vesting Date. 

  

	 	7.2.2	 Except to the extent that the Committee determines otherwise, the Award will lapse to the extent it does not
Vest. 

  

	 	7.2.3	 The Committee will make its determination and any determination under this rule 7 before the offer or
privatisation becomes or is declared unconditional or the meeting(s) of shareholders (as the case may be). 

  

	7.3	 Period for exercise of Options 

An Option which Vests under rule 7.2 or which had already Vested on the date of the event by virtue of which this rule 7 applies, will be
exercisable for a period of one month starting on the date of that event, after which it will lapse to the extent not exercised. 
  

	7.4	 Exchange of awards 

The Committee may decide that any Award will be automatically exchanged for an equivalent award over or in relation to shares in any company
which acquires control of the Company or any affiliate. 
 The equivalent Award will Vest, become exercisable and lapse at the same time(s)
and subject to the same conditions as the original Award but: 
  

	 	7.4.1	 the Committee may waive or amend any Performance Condition; and 

 

	 	7.4.2	 any reference to ‘the Company’ will be to the company which acquires control of the Company or, if
different, the company whose shares are subject to the equivalent award. 

 To the extent that an Award is exchanged under
this rule 7.4, it will not Vest under rule 7.2. 
 Restricted Shares will be cancelled or transferred in consideration of the grant of an
equivalent award of Restricted Shares. The Participant will do all things necessary to facilitate the exchange. 
  

	7.5	 Commencement of winding-up of the Company 

Notwithstanding anything to the contrary, no Restricted Shares or Shares of the Company shall be issued or transferred upon and from
commencement of winding up of the Company and all related Participant’s Awards shall lapse immediately before commencement of winding up of the Company. 

  
 11 

	7.6	 Definitions 

In this rule 7, “Committee” means those people who were members of the Committee immediately before the event by virtue of
which this rule applies. 
  

	8	 Changing the Plan and termination 

 

	8.1	 Power to amend 

The Committee may in its sole discretion at any time change the Plan in any way, including any Performance Condition or other terms of an Award
already granted (even if such amendment is to the detriment of the Participant). 
  

	8.2	 Termination 

The Plan will terminate on the tenth anniversary of Listing or such earlier date as the Committee may determine. No further Awards may be
granted after termination but termination will not affect Awards previously granted. 
  

	9	 General 

  

	9.1	 Terms of employment 

 

	 	9.1.1	 This rule 9.1 applies during and after the employment of a Participant and after the termination, whether or
not the termination is lawful. 

  

	 	9.1.2	 Nothing in the rules or the operation of the Plan forms part of the contract of employment of a Participant.
The rights and obligations arising from the employment relationship between the Participant and the employer are separate from, and are not affected by, the Plan. Participation in the Plan does not create any right to, or expectation of, continued
employment. 

  

	 	9.1.3	 No Participant or eligible Employee has a right to participate in the Plan. Participation in the Plan or the
grant of Awards on a particular basis in any year does not create any right to or expectation of participation in the Plan or the grant of Awards on the same basis, or at all, in any future year. 

 

	 	9.1.4	 The terms of the Plan do not entitle the Participant to the exercise of any discretion in the
Participant’s favour. 

  

	 	9.1.5	 The Participant will have no claim or right of action in respect of any decision, omission or discretion, which
may operate to the disadvantage of the Participant even if it is unreasonable, irrational, capricious, arbitrary or might be regarded as being in breach of the duty of trust and confidence (and/or any other implied duty) between the Participant and
the employer. 

  

	 	9.1.6	 No Participant has any right to compensation for any loss in relation to the Plan, including any loss in
relation to: 

  

	 	(i)	 any loss or reduction of rights or expectations under the Plan in any circumstances (including lawful or
unlawful termination of employment); 

  

	 	(ii)	 any exercise of a discretion or a decision taken in relation to an Award or to the Plan, or any failure to
exercise a discretion or take a decision; 

  

	 	(iii)	 the operation, suspension, termination or amendment of the Plan. 

  
 12 

	9.2	 Committee’ decisions final and binding 

The decision of the Committee on the interpretation of the Plan or in any dispute relating to an Award or matter relating to the Plan will be
final and conclusive. 
  

	9.3	 Documents sent to shareholders 

The Company is not required to send to Participants copies of any documents or notices normally sent to the holders of its Shares. 

 

	9.4	 Costs 

The Company will pay the costs of introducing and administering the Plan. The Company may ask a Participant’s employer to bear the costs
in respect of an Award to that Participant. 
  

	9.5	 Consents 

All allotments, issues and transfers of Shares will be subject to any necessary consents under any relevant enactments or regulations for the
time being in force in any country. The Participant is responsible for complying with any requirements to obtain or avoid the necessity for any such consent. 
  

	9.6	 Share rights 

Shares issued to satisfy Awards under the Plan will rank equally in all respects with the Shares in issue on the date of allotment. They will
not rank for any rights attaching to Shares by reference to a record date preceding the date of allotment. Where Shares are transferred to a Participant, including a transfer out of treasury, the Participant will be entitled to all rights attaching
to the Shares by reference to a record date on or after the transfer date. The Participant will not be entitled to rights before that date. 
  

	9.7	 Data protection 

By participating in the Plan the Participant consents to the holding and processing of personal information provided by the Participant to the
Group, trustee or third party service provider, for all purposes relating to the operation of the Plan. These include, but are not limited to: 
  

	 	9.7.1	 administering and maintaining Participant records; 

 

	 	9.7.2	 providing information to the Group, trustees of any employee benefit trust, registrars, brokers or third party
administrators of the Plan; 

  

	 	9.7.3	 providing information to future purchasers or merger partners of the Company, the Participant’s employing
company, or the business in which the Participant works; 

  

	 	9.7.4	 transferring information about the Participant to a country or territory outside the Participant’s home
country that may not provide the same statutory protection for the information as that country. 

 The Participant is
entitled, on payment of a fee, to a copy of the personal information held about him or her in connection with the Plan. If anything is inaccurate the Participant has the right to have it corrected. 

  
 13 

	9.8	 Notices 

  

	 	9.8.1	 Any information or notice to a person who is or will be eligible to be a Participant under or in connection
with the Plan may be posted, or sent by electronic means, in such manner to such address as the Company considers appropriate, including publication on any intranet. 

 

	 	9.8.2	 Any information or notice to the Company or other duly appointed agent under or in connection with the Plan may
be sent by post or transmitted to it at its registered office or such other place, and by such other means, as the Committee or duly appointed agent may decide and notify Participants. 

 

	 	9.8.3	 Notices sent by post will be deemed to have been given on the second day after the date of posting. However,
notices sent by or to a Participant who is working overseas will be deemed to have been given on the seventh day after the date of posting. Notices sent by electronic means, in the absence of evidence to the contrary, will be deemed to have been
received on the day after sending. 

  

	9.9	 Governing law and jurisdiction 

The Plan and any Award operate subject to the memorandum and articles of association of the Company and any applicable law to which the Company
is subject. The Plan and any Award granted hereunder shall be governed by and construed in accordance with the laws of the State of New York. 

  
 14EX-10.4

 Exhibit 10.4 

SHARES PURCHASE AGREEMENT 

THIS SHARES PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of July 2, 2019 by and among: 

 

	1.	 Genetron Holdings Limited
(泛生子基因(控股)有限公司), an exempted company with limited liability organized and existing under the laws of
the Cayman Islands (the “Company”); 

  

	2.	 Genetron Health(Hong Kong) Company Limited
(泛生子基因(香港)有限公司
), a company organized and existing under the laws of Hong Kong (the “HK Co.”); 

  

	3.	 Genetron (Tianjin) Co., Ltd.
(天津泛生子有限公司), a wholly foreign owned enterprise organized and existing under the laws of the People’s Republic of China (the
“PRC”, for the purpose of this Agreement only, excluding Hong Kong Special Administrative Region, Macaw Special Administrative Region and Taiwan) (the “WFOE”); 

 

	4.	 Genetron Health (Beijing) Co., Ltd.
(北京泛生子基因科技有限公司), a limited liability company organized and existing under the laws of PRC (the
“PRC Affiliate”); 

  

	5.	 Each of the persons as set forth in Schedule 1-1 attached hereto
(the “Founders” and each, a “Founder”). 

  

	6.	 The entity as set forth in Schedule 1-2 attached hereto (the
“BVI Company”).; and 

  

	7.	 Each of the entities as set forth in Schedule 2 attached hereto (the “Investors” and
each, an “Investor”). 

 The Company, the HK Co., the WFOE, the PRC Affiliate and all their direct or
indirect subsidiaries are referred to collectively herein as the “Group Companies”, and each a “Group Company”. 

RECITALS 

A.    The Company desires to issue and sell to the Investors, and the Investors desire to purchase from the Company certain
number of Ordinary Shares and Preferred Shares on the terms and conditions set forth in this Agreement. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

  
 1 

 ARTICLE I 

AGREEMENT TO PURCHASE AND SELL SHARES 

SECTION 1.01 Agreement to Purchase and Sell Purchased Shares. 

Subject to the terms and conditions set forth herein, the Company agrees to issue and sell to each of the Investors, and each of the Investors
shall severally and not jointly, purchase from the Company that number of Ordinary Shares and/or Preferred Shares (the “Purchased Shares”) as set forth opposite such Investor’s name on Schedule 2, at the aggregate
purchase price set forth opposite such Investor’s name in Schedule 2 (the “Purchase Price”) upon the Closing (as defined in the Section 2.01 below), and having the rights, privileges and restrictions as set forth in
the Second Amended and Restated Memorandum and Articles of Association of the Company attached hereto as Exhibit A (the “Restated Articles”), the Shareholders Agreement to be entered into at the Closing and attached hereto as
Exhibit B (the “Shareholders Agreement”), and the subscriptions details attached hereto as Schedule 2. The ordinary shares of the Company issuable upon conversion of the applicable Purchased Shares will be hereinafter
referred to as the “Conversion Shares”. 
 SECTION 1.02 Transfer of Funds. 

Each of the Investors shall pay their respective Purchase Price by wire transfer of United States dollars (for the avoidance of doubt, the
amount of such US dollars shall be calculated and determined in accordance with the foreign exchange rate as quoted by the People’s Bank of China on the day such payment is remitted, namely, the intermediate ratio of USD/CNY exchange) in
immediately available funds to a designated account of the Company as soon as practicable after the Closing but in no event later than twenty (20) business days or at such other time as the Company and the Investors may mutually agree in
writing after all the following conditions have been satisfied or waived by the relevant Investors: (i) the Company shall have delivered wire transfer instructions to such Investor, (ii) with respect to Tianjin Kangyue (as defined in
Schedule 2), Tianjin Yuanjufu (as defined in Schedule 2) and Parkland Medtech Limited, the PRC Affiliate shall have duly completed the registration regarding the reduction of registered capital
of中源协和细胞基因工程股份有限公司,
中金康瑞壹期(宁波)股权投资基金合伙企业(有限合伙)
and深圳鹏瑞集团有限公司in PRC Affiliate with State Administration for Market Regulation or its local counterparts, (iii) with respect to Tianjin Kangyue,
中金康瑞壹期(宁波)股权投资基金合伙企业(有限合伙)
shall have received RMB 3 million from the PRC Affiliate or other Person as its total consideration of capital reduction, (iv) with respect to Genetron Jun’an (as
defined in Schedule 2), Genetron Juncheng (as defined in Schedule 2), Tianjin Kangyue, Tianjin Yuanjufu and Tianjin Tianshu (as defined in Schedule 2) (collectively the “ODI Investors”), such ODI Investors shall have completed the
registration and other procedures required under applicable PRC laws relating to the overseas direct investment (“ODI Registration”), including filing with National Development and Reform Commission or its local counterparts
regarding overseas direct investment project, registration with Ministry of Commerce or its local counterparts regarding enterprise established through overseas direct investment and foreign exchange registration and purchasing with commerce bank
with foreign exchange business as authorized by State Foreign Exchange Bureau or its local counterparts. 

  
 2 

 SECTION 1.03 Post-Investment Capitalization Structure. 

Following the full issue and sale of the Purchased Shares, the post-investment capitalization structure of the Company on an as-converted and fully-diluted basis shall be as set forth in Schedule 3. 
 ARTICLE II 

CLOSINGS; DELIVERY 

SECTION 2.01 Closing. 

The closing of the issuance and sale of the Purchased Shares shall take place remotely via the exchange of documents and signatures as soon as
practicable after all the closing conditions as set forth in Article VI and Article VII hereof have been satisfied or waived (other than those conditions to be satisfied at the Closing, but subject to the satisfaction or otherwise written waiver
thereof at the Closing), or at such other time and place as the Company and the Investors may mutually agree in writing (the “Closing”, and the date for Closing is defined as the “Closing Date”). For the avoidance
of doubt, each Investor has the right, at its sole discretion, to proceed with the Closing under the terms and conditions hereof, and each Investor’s decision to proceed with the Closing shall be independent from that of each other Investor.

 SECTION 2.02 Delivery. 

At the Closing, in addition to any items the delivery of which is made an express condition to the Investors’ obligations at the Closing
pursuant to Article VI, the Company shall, and the Founders shall cause the Company to, deliver to each of the Investors (i) a copy of updated register of members of the Company showing such Investor as the holder of Purchased Shares
purchased by such Investor hereunder, certified as true by the registered agent of the Company, (ii) a copy of updated register of directors of the Company, showing the appointment of the new directors, certified as true by the registered agent
of the Company, (iii) a copy or copies of duly issued share certificate or certificates issued in the name of such Investor representing the class, series and number of Purchased Shares purchased by such Investor pursuant to Section 1
hereunder, duly signed for and on behalf of the Company (the original of which shall be delivered to the Investors within five (5) business days after the Closing); and (iv) a copy of the good standing certificate with respect to the
Company dated not more than thirty (30) days prior to Closing. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF THE SELLER PARTIES 

The Group Companies, the BVI Company and the Founders (collectively, the “Seller Parties” and individually, a “Seller
Party”) hereby jointly and severally represent and warrant to the Investors, as of the date hereof and as of the Closing, that each of the statements as follows is true, correct and complete. 

  
 3 

 SECTION 3.01 Organization, Standing. 

Each Seller Party (to the extent not a natural Person) is duly organized, validly existing and in good standing (or equivalent status in the
relevant jurisdiction) under, and by virtue of, the laws of the place of its incorporation or establishment and has all requisite power and authority to own its properties and assets and to carry on its business as now conducted and as proposed to
be conducted, and to perform each of its obligations hereunder and under any agreement contemplated hereunder to which it is a party. Each of the Seller Parties is not in receivership or liquidation; no steps have been taken to enter into
liquidation; and no petition has been presented for winding up any Seller Parties; and there are no grounds on which a petition or application might be based for the winding up or appointment of a receiver of any Seller Parties. 

SECTION 3.02 Capitalization. 

The authorized share capital of the Company consists of the following: 

(a) Ordinary Shares. Immediately prior to the Closing, a total of 2,328,917,000 authorized ordinary shares, par value US$ 0.00002 per
share, of the Company (the “Ordinary Shares”), of which 5 shares are issued and outstanding. 
 (b) Preferred
Shares. Immediately prior to the Closing, (i) a total of 47,600,000 authorized series A-1 preferred shares, par value US$ 0.00002 per share, of the Company, of which none was issued and outstanding
(the “Series A-1 Preferred Shares”); (ii) a total of 19,760,000 authorized series A-2 preferred shares, par value US$ 0.00002 per share, of the Company,
of which none was issued and outstanding (the “Series A-2 Preferred Shares”, collectively with Series A-1 Preferred Shares, the “Series A
Preferred Shares”); (iii) a total of 43,363,500 authorized series B preferred shares, par value US$ 0.00002 per share, of the Company, of which none was issued and outstanding (the “Series B Preferred Shares”); (iv) a total
of 60,359,500 authorized series C preferred shares, par value US$ 0.00002 per share, of the Company, of which none was issued and outstanding (the “Series C Preferred Shares”, collectively with Series A Preferred Shares and Series B
Preferred Shares, the “Preferred Shares”). 
 (c) Options, Reserved Shares. The Company has reserved enough Ordinary
Shares for issuance upon the conversion of Preferred Shares. Except for (i) the conversion privileges of the Preferred Shares, (ii) the 33,961,500 Ordinary Shares reserved for issuance to employees pursuant to the Company’s employee
share option plans (the “ESOP”) to be approved by the board of directors of the Company (the “Board of Directors”), and (iii) the preemptive rights provided in the Shareholders Agreement, there are no options,
warrants, conversion privileges, agreements or rights of any kind with respect to the issuance or purchase of the shares of any Group Company. Apart from the exceptions noted in this Section 3.02(c), the Shareholders Agreement and Control
Documents (as defined in the Section 6.10 below), no shares (including the Purchased Shares and Conversion Shares) of any Group Company’s outstanding share capital, registered capital, or shares issuable upon exercise or exchange of any
outstanding options or other shares issuable by any Group Company, are subject to any preemptive rights, rights of first refusal or other rights of any kind to purchase such shares (whether in favor of any Group Company or any other person). 

  
 4 

 SECTION 3.03 Due Authorization. 

All corporate action on the part of the Seller Parties (excluding PRC Affiliate’s direct or indirect subsidiaries) and, as applicable,
their respective officers, directors and shareholders necessary for (i) the authorization, execution and delivery of, and the performance of the obligations of the Seller Parties (excluding PRC Affiliate’s direct or indirect subsidiaries)
under this Agreement and the Shareholders Agreement and the various agreements, instruments or documents attached to or entered into in connection with this Agreement (collectively, “Ancillary Agreements”, and collectively with this
Agreement, the Shareholders Agreement, the “Transaction Documents”), the Restated Articles, the certificate of incorporation or other equivalent corporate charter documents of any of the Group Companies (collectively with the
Restated Articles, the “Constitutional Documents”) and (ii) the authorization, issuance, reservation for issuance and delivery of all of the Purchased Shares being sold under this Agreement and of the Conversion Shares has been
taken or will be taken prior to the Closing. Each of the Transaction Documents and the Constitutional Documents is or will, upon its execution be a valid and binding obligation of each Seller Parties (excluding PRC Affiliate’s direct or
indirect subsidiaries) enforceable in accordance with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally and to general
equitable principles. 
 SECTION 3.04 Valid Issuance of Purchased Shares. 

The Purchased Shares are, and Conversion Shares when issued, sold and delivered in accordance with the terms of this Agreement will be, duly
and validly issued, fully paid and non-assessable and will be free of any Encumbrance (as defined below), other than any Encumbrances arising under the Restated Articles, the Shareholders Agreement and other Transaction Documents.
“Encumbrance” means any claim, mortgage, lien, pledge, option, charge, security interest, encumbrance or other similar right of any third parties, whether voluntarily incurred or arising by operation of law, and includes any
agreement to grant any of the foregoing in the future. The issuance of the Purchased Shares is and will be in full compliance with the requirements of all applicable securities laws and regulations including, to the extent applicable, the
registration and prospectus delivery requirements of the Securities Act, or in compliance with applicable exemptions therefrom, and all other provisions of applicable securities laws and regulations. 

SECTION 3.05 Litigation. 

There is no action, suit, proceeding, claim, arbitration or investigation pending or currently threatened against any Group Company. 

SECTION 3.06 Compliance with Laws; Consents and Permits. 

None of any Group Company is or has been in violation of any material respect of any applicable statute, rule, regulation, order or restriction
of any domestic or foreign government or any instrumentality or agency thereof regarding to the conduct of its business or the ownership of its properties. All consents, licenses, permits, approvals, orders, authorizations or registrations,
qualifications, designations, declarations or filings by or with any governmental authority and any third party which are required to be obtained or made by each Group Company in connection with the consummation of the transactions contemplated
hereunder shall have been obtained or made prior to and shall be fully effective as of the Closing (if it occurs). 

  
 5 

 SECTION 3.07 Disclosure. 

No representation or warranty by any Seller Party in this Agreement or in any Transaction Document and no information or materials provided by
any Seller Party to the Investors in connection with the negotiation or execution of this Agreement or any agreement contemplated hereby contains or will contain any untrue statement of a material fact, or omits or will omit to state any material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances in which they are made, not misleading. 

SECTION 3.08 Approvals. 

Each approval, authorization or consent which is required to be obtained by each Group Company (excluding PRC Affiliate’s direct or
indirect subsidiaries) in connection with the consummation of the transactions contemplated under this Agreement and the other Transaction Documents will have been obtained prior to and be effective as of the Closing. 

SECTION 3.09 Non-Contravention.  

The execution, delivery and performance by each Seller Party of and compliance with this Agreement and the other Transaction Documents to which
it is a party, and the consummation of the transactions contemplated hereby and thereby will not result in (i) any violation, breach or default, or be in conflict with or constitute, with or without the passage of time or the giving of notice
or both, a default under (a) the constitutional documents of such Seller Party, (b) any term or provision of any material contract to which such Seller Party is a party or by which it may be bound, or (c) any applicable law,
(ii) the creation or imposition of any encumbrance upon, or with respect to, any of the properties or rights of any Seller Party with Material Adverse Effect on the Company or its business (except for such encumbrance created by the Transaction
Documents), or (iii) any termination, modification, cancellation, or suspension of any right of, or any augmentation or acceleration of any obligation of, any Seller Party. “Material Adverse Effect” means any event,
circumstance, occurrence or non-occurrence, arising or occurring, that is or would reasonably be expected to (i) have a material adverse effect on the business, operations, assets or liabilities; or
(ii) result or would reasonably be expected to result in any invalidity, non-bindingness or unenforceability of this Agreement or any other agreements related in the transactions contemplated hereunder.

 SECTION 3.10 Circular 37 Registrations. 

Each of the Founders, who is a “domestic resident” (as defined in Circular 37) has duly obtained the foreign exchange registration
with the competent local branch of the State Administration of Foreign Exchange in respect of his/her beneficial ownership of the holding company which holds the equity interest of the Company as required under Circular 37. 

  
 6 

 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF THE INVESTORS 

Each of the Investors hereby severally and not jointly represents and warrants to the Company as follows: 

SECTION 3.11 Authorization. 

Such Investor has all requisite power, authority and capacity to enter into this Agreement, and the Shareholders Agreement, and to perform its
obligations under this Agreement, and the Shareholders Agreement. This Agreement has been duly authorized, executed and delivered by such Investor. This Agreement and the Shareholders Agreement, when executed and delivered by such Investor, will
constitute valid and legally binding obligations of such Investor, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally and to general
equitable principles. 
 SECTION 3.12 Purchase for Own Account. 

The Purchased Shares and the Conversion Shares will be acquired for such Investor’s own account, not as a nominee or agent, and not with a
view to or in connection with the sale or distribution of any part thereof. 
 ARTICLE V 

COVENANTS OF THE SELLER PARTIES 

The Seller Parties hereby jointly and severally covenant to the Investors as follows: 

SECTION 4.01 Availability of Ordinary Shares. 

At all times there shall be made available, free of any Encumbrances, for issuance and delivery upon conversion of the Purchased Shares such
number of Ordinary Shares or other shares in the share capital of the Company as are from time to time issuable upon conversion of the Purchased Shares from time to time, and will take all steps necessary to increase its authorized share capital to
provide for sufficient number of Ordinary Shares issuable upon conversion of the Purchased Shares. 
 SECTION 4.02 File of Articles.

 Within five (5) business days following the Closing, the Restated Articles together with the special or written shareholders
resolution on approving its adoption shall have been duly filed with the Registrar of Companies in the Cayman Islands, with the evidence duly delivered to the Investors. 

SECTION 4.03 Reorganization. 

The Seller Parties shall make commercially reasonable efforts to complete and cause completed all actions contemplated under the reorganization
memorandum approved by the then shareholders of the PRC Affiliate. 

  
 7 

 SECTION 4.04 Compliance with Laws. 

The Group Companies shall, and each of the Seller Parties shall cause the Group Companies to, use their respective reasonable best efforts to
conduct their respective business as now conducted and as proposed to be conducted in all material respects in compliance with all applicable laws on a continuing basis, including but not limited to the laws regarding foreign investments, corporate
registration and filing, import and export, customs administration, foreign exchange, advertisement, intellectual property rights, taxation, labor and social welfare, welfare funds, social benefits, medical benefits, insurance, retirement benefits,
and pensions or the like. 
 SECTION 4.05 Key Persons’ Service Term. 

Without prior written consent of each Investor, Wang Sizhen (王思振) and Yan Hai (阎海) (collectively the “Key
Persons”, and each a “Key Person”) covenant not to resign from the Group Companies voluntarily within five (5) years (“Minimum Service Term”) since October 10, 2017. If any Key Person resigns
voluntarily with the prior consent of each Investor, the shares of the Company directly or indirectly held by such Key Person shall be redeemed by the Company in any way legally permitted at certain redemption price mutually agreed by the Company,
such Key Person, and the Investors, and the number of shares to be redeemed of such Key Person is equal to the product obtained by multiplying (x) the aggregate number of the shares in the Company directly or indirectly by such Key Person by
(y) a fraction, the numerator of which is the number of the month(s) remaining to be served for by such Key Person and the denominator of which is the total number of the month(s) of the Minimum Service Term. 

SECTION 4.06 Transfer of Intellectual Properties. 

Any intellectual property obtained or owned by any Founder that is material to the Group Companies’ business operation shall, to the
maximum extent permitted by the applicable laws and as soon as practical, be transferred to the Group Companies with no compensation. 

SECTION 4.07 Non-Competition. 

Key Persons covenant not to, directly or indirectly, own or participate in business of molecular diagnosis outside the Group Companies which is
substantially competitive with the Group Companies’ business (other than as a holder of less than five percent (5%) of the outstanding capital stock of a company without decision rights). 

SECTION 4.08 Accounting Standards. 

The Group Companies shall establish and maintain generally accepted accounting standards which comply with all applicable laws. 

SECTION 4.09 Use of Proceeds 

Solely with respect to Tianjin Yuanjufu, the Purchase Price paid by Tianjin Yuanjufu shall be used exclusively for the purpose of repurchasing
the equity interest held by 中源协和细胞基因工程股份有限公司 in the PRC Affiliate. 

  
 8 

 SECTION 4.10 Use of Investors’ Name or Logo. 

Without the prior written consent of any Investor, and whether or not such Investor is then the shareholders of the Company, none of the Group
Companies nor their shareholders (excluding the Investors) shall use, publish or reproduce the names of any Investor or any similar names, trademarks or logos in any of their marketing, advertising or promotion materials or otherwise for any
marketing, advertising or promotional purposes in relation to any Group Company or the transactions contemplated hereunder, except for (i) the fact of the equity investments and shareholding in the Group Companies by the Investors (and in any
such case shall not disclose the aggregate or individual investment amounts, pricing or ownership percentage, or any of the term of this Agreement, the Shareholders Agreement or any of the Ancillary Agreements); or (ii) required by the
competent laws or regulatory authority. 
 ARTICLE VI 

CONDITIONS OF INVESTORS’ OBLIGATIONS AT CLOSING 

The obligations of each Investor to consummate the Closing under Section 2.01 of this Agreement are subject to the fulfillment, to the
satisfaction of such Investor (or waiver thereof by such Investor) on or prior to the Closing Date, of the following conditions: 
 SECTION
5.01 Representations and Warranties True and Correct. 
 The representations and warranties made by the Seller Parties in Article
III hereof shall be true and correct and complete when made, and shall be true and correct and complete as of the Closing Date with the same force and effect as if they had been made on and as of such date, subject to changes contemplated by
this Agreement. 
 SECTION 5.02 Performance of Obligations. 

Each Founder and each Group Company shall have performed and complied with all agreements, obligations and conditions that are required by the
Transaction Documents to be performed or complied with by it on or before the Closing. 
 SECTION 5.03 Proceedings and Documents.

 All corporate and other proceedings in connection with the transactions contemplated hereby and all documents and instruments incident to
such transactions shall be satisfactory in substance and form to the Investors, and the Investors shall have received all such counterpart originals or certified or other copies of such documents as they may reasonably request. 

SECTION 5.04 Approvals, Consents and Waivers. 

Each Group Company (excluding PRC Affiliate’s direct or indirect subsidiaries) shall have obtained any and all approvals, consents and
waivers necessary for consummation of the transactions contemplated by this Agreement, including, but not limited to, (i) all permits, authorizations, approvals, consents or permits of any governmental authority or regulatory body,
(ii) resolutions approved by the shareholders and boards of directors of each Group Company (excluding PRC Affiliate’s direct or indirect subsidiaries) or its shareholders (if applicable), and (iii) the waiver by the existing
shareholders of the Company of any anti-dilution rights, rights of first refusal, preemptive rights and all similar rights in connection with the issuance of the Purchased Shares at the Closing. 

  
 9 

 SECTION 5.05 Amendment to Constitutional Documents. 

The Restated Articles shall have been duly adopted by the Company by all necessary corporate actions of its board of directors and its
shareholders. 
 SECTION 5.06 Register of Members. 

Each of the Investors shall have received a copy of the Company’s register of members, certified by the registered agent of the Company as
true and complete as of the date of the Closing, updated to show such Investor as the holder of the Purchased Shares purchased by such Investor hereunder as of the Closing. 

SECTION 5.07 Appointment of Directors and Board Observer. 

The Company shall have taken all necessary corporate action such that (i) immediately prior to the Closing their respective board of
directors shall have four (4) members, which members shall be He Weiwu, Yan Hai, Wang Sizhen, and Wu Xia, and evidence thereof shall have been delivered to each Investor;(ii) SUPERPOWER INVESTMENTS LTD. shall be entitled to appoint an observer
to the board of directors of the Company. 
 SECTION 5.08 Execution of Transaction Documents. 

The Company shall have delivered to the Investors the Transaction Documents, duly executed by the Company and all other parties thereto (except
for the Investors). 
 SECTION 5.09 Execution of Director Indemnification Agreement. 

The Company shall have delivered to Tianjin Kangyue a director indemnification agreement in the form attached hereto as Exhibit C, duly
executed by the Company, Tianjin Kangyue and Wu Xia. 
 SECTION 5.10 Execution of Control Documents. 

The Company shall have caused a set of Control Documents in the form as set forth in Exhibit D to be entered into between the WFOE, the
PRC Affiliate, and all the then shareholders of the PRC Affiliate, which, once taking effect according to the terms and conditions therein, will enable WFOE to exercise effective control over the PRC Affiliate and its subsidiaries (the
“Control Documents”): (i) Exclusive Option Agreement; (ii) Equity Pledge Agreement; (iii) Exclusive Business Cooperation Agreement; (iv) Power of Attorney and (v) Spousal Consent. 

SECTION 5.11 Legal Opinion. 

The Company shall have delivered to each Investor a legal opinion in form and substance to the satisfaction of each Investor issued by the
Cayman Islands counsel of the Company, dated as of the Closing Date. 

  
 10 

 ARTICLE VII 

CONDITIONS TO THE COMPANY’S OBLIGATIONS AT THE CLOSING 

The obligations of the Company under this Agreement at the Closing with respect to the Investors are subject to the fulfillment, on or prior
to the Closing Date of the following conditions: 
 SECTION 7.01 Representations and Warranties. 

The representations and warranties of the Investors contained in Article IV hereof shall be true and correct as of the Closing Date. 

SECTION 7.02 Execution of Transaction Documents. 

The Investors shall have executed and delivered to the Company the Transaction Documents to which it is a party. 

ARTICLE VIII 

MISCELLANEOUS 
 SECTION
8.01 Governing Law. 
 This Agreement shall be governed by and construed exclusively in accordance with the laws of the Hong Kong SAR
without regard to principles of conflicts of law thereunder. 
 SECTION 8.02 Successors and Assigns. 

Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors and administrators of the parties hereto whose rights or obligations hereunder are affected by such amendments. This Agreement and the rights and obligations therein may not be assigned by the Seller Parties without the
written consent of the Investors. Notwithstanding the foregoing, Tianjin Kangyue shall be entitled to assign the rights and obligations under this Agreement to its affiliates, affiliated partnerships or funds managed by or affiliated with it
or any of their respective directors, officers or partners without prior written notice to other parties, provided that such successor shall not be the Competitor of the Group Companies and shall have obtained all necessary approval, authorization
or consent with any governmental authority which are required to be obtained or made in connection with its shareholding in the Company, and the Company and other Parties hereto shall facilitate to effectuate such assignment upon Tianjin
Kangyue’s request and shall waive any rights of first refusal, preemptive rights and all similar rights in connection with such assignment, provided such assignee agrees in writing to be subject to the terms of this Agreement and other
Transaction Documents as if it were an Investor hereunder or thereunder. For the purpose of this Agreement, “Competitor” means, any person who is engaged in the business of molecular diagnosis, which is directly or indirectly
competitive with the Group Companies. 

  
 11 

 SECTION 8.03 Entire Agreement.  

This Agreement, the Shareholders Agreement, any Ancillary Agreements, and the schedules and exhibits hereto and thereto, which are hereby
expressly incorporated herein by this reference constitute the entire understanding and agreement between the parties with regard to the subjects hereof and thereof; provided, however, that nothing in this Agreement or related
agreements shall be deemed to terminate or supersede the provisions of any investment, confidentiality and nondisclosure agreements executed by the parties hereto prior to the date hereof, which agreements shall continue in full force and effect
until terminated in accordance with their respective terms. 
 SECTION 8.04 Termination. 

This Agreement may be terminated prior to the Closing by mutual written Consent of the parties. 

SECTION 8.05 Notices. 

Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement shall be in
writing and shall be conclusively deemed to have been duly given (a) when hand delivered to the other party, upon delivery; (b) when sent by facsimile at the number set forth in Exhibit E hereto, upon receipt of confirmation of
error-free transmission; (c) seven (7) business days after deposit in the mail as air mail or certified mail, receipt requested, postage prepaid and addressed to the other party as set forth in Exhibit E; or (d) three (3) business
days after deposit with an overnight delivery service, postage prepaid, addressed to the parties as set forth in Exhibit E with next business day delivery guaranteed, provided that the sending party receives a confirmation of delivery from
the delivery service provider. 
 Each person making a communication hereunder by facsimile shall promptly confirm by telephone to the
person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity of any such communication. A party may change or supplement the addresses
given above, or designate additional addresses, for purposes of this Section by giving, the other parties written notice of the new address in the manner set forth above. 

SECTION 8.06 Amendments. 

Any term of this Agreement may be amended only with the written consent of the Seller Parties and the Investors. 

SECTION 8.07 Delays or Omissions. 

No delay or omission to exercise any right, power or remedy accruing to any Seller Party or Investor, upon any breach or default of any party
hereto under this Agreement, shall impair any such right, power or remedy of such Seller Party or Investor, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach of default
thereafter occurring; nor shall any waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Seller Party or Investor of any breach of default
under this Agreement or any waiver on the part of any Seller Party or Investor of any provisions or 

  
 12 

 
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law or
otherwise afforded to the Seller Parties and the Investors shall be cumulative and not alternative. 
 SECTION 8.08 Interpretation;
Titles and Subtitles. 
 This Agreement shall be construed according to its fair language. The rule of construction to the effect that
ambiguities are to be resolved against the drafting party shall not be employed in interpreting this Agreement. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be considered in
construing this Agreement. Unless otherwise expressly provided herein, all references to Sections and Exhibits herein are to Sections and Exhibits of this Agreement. As used in this Agreement, the words “include” and “including”,
and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation”. 

SECTION 8.09 Counterparts. 

This Agreement may be executed (including facsimile signature) in any number of counterparts, each of which shall be an original, but all of
which together shall constitute one instrument. 
 SECTION 8.10 Severability. 

If any provision of this Agreement is found to be invalid or unenforceable, then such provision shall be construed, to the extent feasible, so
as to render the provision enforceable and to provide for the consummation of the transactions contemplated hereby on substantially the same terms as originally set forth herein, and if no feasible interpretation would save such provision, it shall
be severed from the remainder of this Agreement, which shall remain in full force and effect unless the severed provision is essential to the rights or benefits intended by the parties. In such event, the parties shall use best efforts to negotiate,
in good faith, a substitute, valid and enforceable provision or agreement which most nearly effects the parties’ intent in entering into this Agreement. 

SECTION 8.11 Confidentiality and Non-Disclosure. 

The parties hereto agree to be bound by the confidentiality and non-disclosure provisions of the
Shareholders Agreement, which shall mutatis mutandis apply. 
 SECTION 8.12 Further Assurances. 

Each party shall from time to time and at all times hereafter make, do, execute, or cause or procure to be made, done and executed such further
acts, deeds, conveyances, consents and assurances without further consideration, which may reasonably be required to effect the transactions contemplated by this Agreement. 

SECTION 8.13 Dispute Resolution. 

Any dispute, controversy, difference or claim arising out of or relating to this Agreement, including the existence, validity, interpretation,
performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or 

  
 13 

 
relating to it shall be referred to and finally resolved by arbitration administered by the Hong Kong International Arbitration Centre (the “HKIAC”) under the HKIAC Administered
Arbitration Rules in force when the Notice of Arbitration is submitted. The law of this arbitration clause shall be Hong Kong law. The seat of arbitration shall be Hong Kong. The number of arbitrators shall be three (3). The arbitration proceedings
shall be conducted in English. 
 SECTION 8.14 Adjustments for Share Splits, Etc. 

Wherever in this Agreement there is a reference to a specific number of shares of a class or series of shares of the Company, then, upon the
occurrence of any subdivision, combination or share dividend of such shares, the specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted to reflect the effect on the outstanding shares of such class
or series of shares by such subdivision, combination or share dividend. 
 SECTION 8.15 Indemnification. 

The Seller Parties shall jointly and severally indemnify, defend and hold harmless the Investors, and their affiliates, directors, officers,
employees, agents, successors and assigns (each, an “Indemnified Person”) from and against any loss suffered or incurred by the Indemnified Person as a result of or based upon or arising from any inaccuracy in or breach or non-performance of any of the representations, warranties, covenants or agreements made by any Seller Party in or pursuant to the Transaction Documents or any fraud or willful misconduct for any Seller Party in
connection with the transactions contemplated by the Transaction Documents. This Section 8.15 shall survive any termination of this Agreement. 

SECTION 8.16 Independent Nature of Investors’ Obligations and Rights. 

The obligations of each Investor under this Agreement and the other Transaction Documents are several and not joint, and no Investor is
responsible in any way for the performance or conduct of any other Investor in connection with the transactions contemplated hereby. Nothing contained herein or in any other Transaction Document, and no action taken by any Investor pursuant hereto
or thereto, shall be or shall be deemed to constitute a partnership, association, joint venture, or joint group with respect to the Investors. Each Investor agrees that no other Investor has acted as an agent for such Investor in connection with the
transactions contemplated hereby. 
 SECTION 8.17 No Third Parties’ Rights. 

A person who is not a party to this Agreement has no right under the Contracts (Right of Third Parties) Ordinance (Cap. 623) of Hong Kong (the
“Third Party Ordinance”) to enforce any term of this Agreement but this shall not affect any right or remedy which exists or is available apart from the Third Party Ordinance. The consent of any such person not being a party to this
Agreement shall not be required for any amendment or modification to, or termination of, this Agreement. 
 [SIGNATURES ON FOLLOWING PAGE]

  
 14 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	THE COMPANY:
	
	Genetron Holdings Limited (泛生子基因(控股)有限公司)
	/s/ Seal of Genetron Holdings Limited
	
	/s/ Genetron Holdings Limited
	By:	 	 /s/ Wang Sizhen

	Name:	 	Wang Sizhen
	Title:	 	Director
	
	THE HK CO.:
	
	Genetron Health (Hong Kong) Company Limited
	(泛生子基因(香港)有限公司)
	/s/ Seal of Genetron Health (Hong Kong) Company Limited
		
	By:	 	 /s/ Wang Sizhen

	Name:	 	Wang Sizhen
	Title:	 	Director
	
	THE WFOE:
	
	Genetron (Tianjin) Co., Ltd. (天津泛生子有限公司)(Seal)
	/s/ Seal of Genetron (Tianjin) Co., Ltd.
		
	By:	 	 /s/ Wang Sizhen

	Name:	 	Wang Sizhen
	Title:	 	Legal Representative
	
	THE PRC AFFILIATE:
	
	Genetron Health (Beijing) Co., Ltd.
(北京泛生子基因科技有限公司)(Seal
)
	/s/ Seal of Genetron Health (Beijing) Co., Ltd.
		
	By:	 	 /s/ Wang Sizhen

	Name:	 	Wang Sizhen
	Title:	 	Legal Representative

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE BVI COMPANY:

	
	 FHP Holdings Limited

		
	 By:
	 	 /s/ Wang Sizhen

	 Name:
	 	 Wang Sizhen

	 Title:
	 	 Director

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE FOUNDERS:

	
	 /s/ Wang Sizhen

	 Name:
	 	 Wang Sizhen

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE FOUNDERS:

	
	 /s/ Yan Hai

	 Name:
	 	 Yan Hai

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE FOUNDERS:

	
	 /s/ He Weiwu

	 Name:
	 	 He Weiwu

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 EASY BENEFIT INVESTMENT LIMITED

		
	 By:
	 	 /s/ Kung Hung Ka

	 Name:
	 	 Kung Hung Ka 

	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 EASY BEST INVESTMENT LIMITED

		
	 By:
	 	 /s/ Kung Hung Ka

	 Name:
	 	 Kung Hung Ka 

	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 SUPERPOWER INVESTMENTS LTD.

		
	 By:
	 	 /s/ Stone Shi

	 Name:
	 	 Stone Shi

	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 CrowdBees Holdings Limited

		
	 By:
	 	 /s/ Cai Cong

	 Name:
	 	Cai Cong
	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 J&K BIOTECH INVESTMENT CO. LTD.

		
	 By:
	 	 /s/ Zhu Jing

	 Name:
	 	Zhu Jing
	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 IN Healthcare Limited

		
	 By:
	 	 /s/ Zheng Yufen

	 Name:
	 	Zheng Yufen
	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 Parkland Medtech Limited

		
	 By:
	 	 /s/ Xu Hang

	 Name:
	 	Xu Hang
	 Title:
	 	 Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 Genetron Discovery Holdings Limited

	/s/ Seal of Genetron Discovery Holdings Limited
		
	By:	 	 /s/ Jiao Yuchen

	Name:	 	JIAO Yuchen
	Title:	 	Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	 Genetron Alliance Holdings Limited

	/s/ Seal of Genetron Alliance Holdings Limited
		
	By:	 	 /s/ Wang Sizhen

	Name:	 	WANG Sizhen
	Title:	 	Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	Tianjin Genetron Jun’an Business Management Partnership (Limited Partnership)
	
天津今创君安企业管理合伙企业(有限合伙)(
Seal)

	/s/ Seal of Tianjin Genetron Jun’an Business Management Partnership (Limited Partnership)
		
	 By:
	 	 /s/ Wang Sizhen

	 Name:
	 	WANG Sizhen(王思振)
	 Title:
	 	Authorized Signatory
	
	Tianjin Genetron Juncheng Business Management Partnership (Limited Partnership)
	
天津今创君成企业管理合伙企业(有限合伙)(
Seal)

	/s/ Seal of Tianjin Genetron Juncheng Business Management Partnership (Limited Partnership)
		
	 By:
	 	 /s/ Wang Sizhen

	 Name:
	 	Wang Sizhen
	 Title:
	 	Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	Tianjin Kangyue Business Management Partnership (Limited Partnership)
	
天津康悦企业管理合伙企业(有限合伙)
(Seal)

	/s/ Seal of Tianjin Kangyue Business Management Partnership (Limited Partnership)
		
	 By:
	 	 /s/ Wu Xia

	 Name:
	 	Wu Xia
	 Title:
	 	Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	Tianjin Yuanjufu Business Management Partnership (Limited Partnership)
	
天津源聚福企业管理合伙企业(有限合伙)
(Seal)

	/s/ Seal of Tianjin Yuanjufu Business Management Partnership (Limited Partnership)
		
	 By:
	 	 /s/ Wei Zhe

	 Name:
	 	WEI Zhe
	 Title:
	 	Authorized Signatory

 Signature Page of Shares Purchase Agreement 

 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized
representatives to execute this Agreement as of the date and year first above written. 
  

			
	 THE INVESTORS:

	
	Tianjin Tianshu Xingfu Corporation Management L.P.
	
天津天枢幸福企业管理合伙企业(有限合伙)
(Seal)

	/s/ Seal of Tianjin Tianshu Xingfu Corporation Management L.P.
		
	 By:
	 	 /s/ Sun Junjie

	 Name:
	 	Sun Junjie
	 Title:
	 	Authorized Signatory

 Signature Page of Shares Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]